MedTrace Logo

Plasma Concentration of Biological Markers in Placental Abruption

NCT03782168 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2024-09-03

No results posted yet for this study

Summary

This will be a prospective study conducted on women with a suspected/confirmed diagnosis of placental abruption. Maternal blood samples will be taken at various points during the peripartum period. A healthy group of women admitted for delivery will act as a matched control and will have their blood sampled at similar time points. The primary outcome variables will include the total number of micro-particles, the number of micro-particles from each cell line (platelet, placental, endothelial etc.), and protein markers (specifically; placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFLT-1), vascular endothelial growth factor (VEGF), soluble endoglin (sEng)). Secondary outcomes if will examine the correlation between placental micro-particles, biomarkers, and extent of placental abruption.

Conditions

  • Abruptio Placentae

Interventions

OTHER

There is no other intervention, only clinical treatment.

The purpose of this study is to determine how well maternal serum biomarkers and placental micro-particles (MP) correlate with PA. The sensitivity and specificity of these proteins will be analyzed to further increase our understanding of the pathological mechanisms involved in PA.

Sponsors & Collaborators

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Nadir Shawrawi, MD · University of Arkansas

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-31
Primary Completion
2019-01-31
Completion
2021-08-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03782168 on ClinicalTrials.gov